GT Biopharma, Inc.

2.82 USD
-0.10 (-3.42%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

GT Biopharma, Inc. stock is down -63.85% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36% of the previous 49 June’s closed higher than May.

About GT Biopharma, Inc.

GT Biopharma, Inc. focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate, is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company was formerly known as OXIS International, Inc